Trends in Treatment Patterns and Outcomes of Patients With Pulmonary Embolism in Japan, 2010 to 2020: A Nationwide Inpatient Database Study.
epidemiology
extracorporeal membrane oxygenation
factor Xa inhibitors
mortality
pulmonary embolism
thrombolytic therapy
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
20 06 2023
20 06 2023
Historique:
medline:
21
6
2023
pubmed:
11
6
2023
entrez:
10
6
2023
Statut:
ppublish
Résumé
Background The impact of major changes in the treatment practice of pulmonary embolism (PE), such as limited indications for systemic thrombolysis and the introduction of direct oral anticoagulants, is not well documented. This study aimed to describe annual trends in the treatment patterns and outcomes in patients with PE. Methods and Results Using the Japanese Diagnosis Procedure Combination inpatient database from April 2010 to March 2021, we identified hospitalized patients with PE. Patients with high-risk PE were defined as those admitted for out-of-hospital cardiac arrest or who received cardiopulmonary resuscitation, extracorporeal membrane oxygenation, vasopressors, or invasive mechanical ventilation on the day of admission. The remaining patients were defined as patients with non-high-risk PE. The patient characteristics and outcomes were reported with fiscal year trend analyses. Of 88 966 eligible patients, 8116 (9.1%) had high-risk PE, and the remaining 80 850 (90.9%) had non-high-risk PE. Between 2010 and 2020, in patients with high-risk PE, the annual proportion of extracorporeal membrane oxygenation use significantly increased from 11.0% to 21.3%, whereas that of thrombolysis use significantly decreased from 22.5% to 15.5% (
Identifiants
pubmed: 37301745
doi: 10.1161/JAHA.122.028981
pmc: PMC10356020
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e028981Références
Vasc Med. 2020 Oct;25(5):460-467
pubmed: 32790536
Eur Heart J. 2014 Nov 14;35(43):3033-69, 3069a-3069k
pubmed: 25173341
Eur Heart J. 2020 Jan 21;41(4):543-603
pubmed: 31504429
Eur Heart J. 2018 Dec 14;39(47):4196-4204
pubmed: 30137303
Circulation. 2016 Jan 5;133(1):98-103
pubmed: 26719388
Eur Respir J. 2022 Nov 3;60(5):
pubmed: 35487534
BMJ Open. 2013 Apr 29;3(4):
pubmed: 23633419
J Epidemiol. 2017 Oct;27(10):476-482
pubmed: 28142051
J Thromb Haemost. 2010 Jan;8(1):202-4
pubmed: 19878532
Chest. 2012 Feb;141(2 Suppl):e419S-e496S
pubmed: 22315268
Thromb Res. 2019 Dec;184:50-57
pubmed: 31706068
J Am Heart Assoc. 2020 Jan 21;9(2):e014582
pubmed: 31918600
Lancet. 1988 Aug 6;2(8606):293-8
pubmed: 2899718
Lancet. 1993 Feb 27;341(8844):507-11
pubmed: 8094768
J Intensive Care. 2023 Feb 6;11(1):4
pubmed: 36740697
Eur Heart J. 2015 Mar 7;36(10):605-14
pubmed: 24917641
PLoS Med. 2015 Oct 06;12(10):e1001885
pubmed: 26440803
Resuscitation. 2022 Jan;170:285-292
pubmed: 34653550
Arterioscler Thromb Vasc Biol. 2014 Nov;34(11):2363-71
pubmed: 25304324
Chest. 2021 Dec;160(6):e545-e608
pubmed: 34352278
Eur Heart J. 2020 Jan 21;41(4):522-529
pubmed: 31102407
Vasc Med. 2019 Jun;24(3):230-233
pubmed: 30834824
J Crit Care. 2021 Aug;64:245-254
pubmed: 34049258
J Thromb Thrombolysis. 2022 Oct;54(3):524-534
pubmed: 35713842